Northern Trust
VIR icon

Northern Trust’s Vir Biotechnology VIR Stock Holding History

Northern Trust’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6M Buy
1,432,165
+446,730
+45% +$4.25M ﹤0.01% 1976
2026
Q1 		$8.83M Buy
985,435
+136,966
+16% +$1.09M ﹤0.01% 2143
2025
Q4 		$5.12M Sell
848,469
-58,657
-6% -$349K ﹤0.01% 2467
2025
Q3 		$5.18M Sell
907,126
-21,114
-2% -$108K ﹤0.01% 2479
2025
Q2 		$4.68M Sell
928,240
-2,080
-0.2% -$11.2K ﹤0.01% 2492
2025
Q1 		$6.03M Sell
930,320
-134
-0% -$1.19K ﹤0.01% 2323
2024
Q4 		$6.83M Buy
930,454
+51,530
+6% +$406K ﹤0.01% 2337
2024
Q3 		$6.58M Buy
878,924
+45,433
+5% +$395K ﹤0.01% 2319
2024
Q2 		$7.42M Sell
833,491
-25,100
-3% -$241K ﹤0.01% 2167
2024
Q1 		$8.7M Sell
858,591
-78,713
-8% -$802K ﹤0.01% 2126
2023
Q4 		$9.43M Sell
937,304
-61,249
-6% -$560K ﹤0.01% 2119
2023
Q3 		$9.36M Buy
998,553
+21,808
+2% +$311K ﹤0.01% 2056
2023
Q2 		$24M Buy
976,745
+110,365
+13% +$2.77M ﹤0.01% 1465
2023
Q1 		$20.2M Buy
866,380
+87,681
+11% +$2.24M ﹤0.01% 1541
2022
Q4 		$19.7M Sell
778,699
-51,965
-6% -$1.27M ﹤0.01% 1531
2022
Q3 		$16M Sell
830,664
-23,739
-3% -$603K ﹤0.01% 1649
2022
Q2 		$21.8M Buy
854,403
+243,076
+40% +$5.67M ﹤0.01% 1465
2022
Q1 		$15.7M Sell
611,327
-8,180
-1% -$243K ﹤0.01% 1843
2021
Q4 		$25.9M Sell
619,507
-3,142
-0.5% -$123K ﹤0.01% 1588
2021
Q3 		$27.1M Sell
622,649
-28,611
-4% -$1.24M ﹤0.01% 1568
2021
Q2 		$30.8M Buy
651,260
+46,639
+8% +$2.12M 0.01% 1570
2021
Q1 		$31M Sell
604,621
-32,392
-5% -$1.75M 0.01% 1508
2020
Q4 		$17.1M Sell
637,013
-17,808
-3% -$579K ﹤0.01% 1905
2020
Q3 		$22.5M Buy
654,821
+164,032
+33% +$7.06M ﹤0.01% 1533
2020
Q2 		$20.1M Buy
490,789
+381,561
+349% +$12.8M ﹤0.01% 1620
2020
Q1 		$3.74M Buy
109,228
+3,476
+3% +$93.4K ﹤0.01% 2471
2019
Q4 		$1.33M Buy
+105,752
New +$1.42M ﹤0.01% 3300

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Northern Trust's VIR Position: Q2 2026 in Review

Northern Trust increased its Vir Biotechnology (VIR) stake by 45% in Q2 2026, buying an estimated $4.25M and bringing the position to 1,432,165 shares worth $14.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1976.

Northern Trust first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $31M in Q1 2021. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Northern Trust held 1,432,165 shares of Vir Biotechnology worth $14.6M as of Q2 2026.
  • Northern Trust bought 446,730 Vir Biotechnology shares in Q2 2026, an estimated $4.25M.
  • Vir Biotechnology made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #1976 holding.
  • Northern Trust first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • Northern Trust's Vir Biotechnology position peaked at $31M in Q1 2021.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.